ArticleJournal of Taibah University Medical Sciences2025
Article in Journal of Taibah University Medical Sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Because aberrant Rho GTPase signaling has been associated with multiple cancers, it was investigated as a potential target for liver cancer treatment drugs. The important medicinal plant Methods: Polyphenols were identified in the methanolic extract of Results: The polyphenols gallic acid, salicylic acid, caffeic acid, kaempferol, rutin, quercetin, coumarin, ferulic acid, sinapic acid, HB acid, vanillic acid, and chlorogenic acid were found in the methanolic extract of Conclusion: Caffeic acid remained intact and bound the protein structure throughout the simulation run, thus demonstrating a robust interaction between the protein and ligand, and indicating a possible inhibitory effect. Therefore, this compound might have the greatest ability to inhibit the RhoA protein. Further research is required to examine caffeic acid as a potential medication option for future drug development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.